FDA Grants De Novo Authorization for AI-Powered Prostate Cancer Prognostic Software
The risk stratification tool is designed to predict long-term outcomes for patients with non-metastatic prostate cancer.
Read MorePosted by CLP Edit Staff | Aug 25, 2025 | Prostate |
The risk stratification tool is designed to predict long-term outcomes for patients with non-metastatic prostate cancer.
Read MorePosted by CLP Edit Staff | Aug 22, 2025 | Company News |
Cancer diagnostics company adds three clinical advisors and two board members to support commercial growth and platform expansion.
Read MorePosted by CLP Edit Staff | Aug 21, 2025 | Information Technology |
The cloud-based EHR platform now offers real-time lab ordering and results delivery, eliminating the need for separate portals or fax-based communication.
Read MorePosted by CLP Edit Staff | Aug 21, 2025 | POC Rapid Assays |
The app integrates rapid diagnostic testing, artificial intelligence, and telehealth capabilities, while the company’s decentralized clinical trial platform aims to reduce study costs and improve data collection.
Read MorePosted by CLP Edit Staff | Aug 21, 2025 | Molecular Diagnostics |
The Salt Lake City-based company offers four targeted testing options that focus on how genetics influence responses to nutrition, fitness, sleep, and stress management.
Read More